Power3 Medical Products launches Phase II trials for Alzheimer's and Parkinson's diseases blood diagnostic tests

BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on Power3 Medical Products (OTCBB: PWRM), the developer of several blood tests designed for early detection, monitoring and targeting of diseases like Alzheimer's, Parkinson's and breast cancer.

With 10 years of development of their technology and intellectual property, and with commercialization in sight, Power3 is at a critical point in the company's growth. Company CEO, Helen Park told BioMedReports on Tuesday afternoon:

"Power3 Medical Products has recently completed the Phase I Clinical Trials for Alzheimer's and Parkinson's diseases blood diagnostic tests with better than expected results and launched the Phase II clinical trials for both of these diseases. Our Chief Scientific Officer, Dr. Ira Goldknopf, is reporting new information on these results at the BIT meeting in China this week."

The medical community's interest in these new tests, huge market potential, pending positive news, partnerships and technical analysis here look very solid and the stock will open on Wednesday roughly three cents away from potential break-out over a previous level of resistance and previous high.

The complete report is available now at BioMedReports.com:

http://biomedreports.com/component/content/article/56-top-leading-news/18487-ready-to-run-power3-medical-products-otcpwrm.html

Source:

BioMedReports

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vitamin D may lower blood pressure in older people with obesity